Instructions
If you are interested in learning more about your possible participation in this clinical trial, please complete the form. Your information will be forwarded directly to the sponsoring company.
IPSS low or intermediate-1 risk non-del(5q) MDS that is relapsed/refractory to ESA treatment; RBC transfusion dependent; an Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1 or 2; and no prior treatment with either a hypomethylating agent or lenalidomide.
- Prior treatment with a hypomethylating agent (example [eg], azacitidine, decitabine)
- Prior treatment with lenalidomide
- Has received an erythropoiesis-stimulating agent (ESA) or any chemotherapy, immunomodulatory, or immunosuppressive therapy within 4 weeks prior to study entry (8 weeks for long-acting ESAs)